Spyre Therapeutics (SYRE) Earnings Date, Estimates & Call Transcripts $15.89 -0.09 (-0.56%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$15.66 -0.23 (-1.44%) As of 10/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Spyre Therapeutics Earnings Summary Spyre Therapeutics announced Q2 2025 earnings on August 5, 2025, reporting an EPS of -$0.49, which beat analysts' consensus estimates of -$0.73 by $0.24. With a trailing EPS of -$3.40, Spyre Therapeutics' earnings are expected to grow next year, from ($4.46) to ($3.99) per share. Upcoming Q3 Earnings DateNov. 6Before Market OpensEstimatedConsensus EPS (Aug. 5) -$0.73 Actual EPS (Aug. 5) -$0.49 Beat By $0.24 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)SYRE Upcoming EarningsSpyre Therapeutics' next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules. Powered by Get Spyre Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataSYRE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SYRE Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Spyre Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.86-$0.83-$0.85Q2 20252-$0.83-$0.78-$0.81Q3 20252-$0.84-$0.75-$0.80Q4 20252-$0.85-$0.76-$0.81 Spyre Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/6/2025(Estimated)--------8/5/2025Q2 2025-$0.73-$0.49+$0.24-$0.49--5/8/2025Q1 2025-$0.76-$0.74+$0.02-$0.74--2/27/2025Q4 2024-$0.89-$0.81+$0.08-$0.81$2.10M-11/7/2024--$0.80-$1.36 -$0.56-$1.36--8/7/2024--$0.90-$0.86+$0.04-$0.86--5/13/2024--$0.90-$1.20 -$0.30-$1.20--2/29/2024Q4 2023-$0.48-$2.28 -$1.80-$0.51--11/9/2023Q3 2023-$0.44-$3.43 -$2.99$2.48-- Spyre Therapeutics Earnings - Frequently Asked Questions When is Spyre Therapeutics' earnings date? Spyre Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based off last year's report dates. Learn more on SYRE's earnings history. Did Spyre Therapeutics beat their earnings estimates last quarter? In the previous quarter, Spyre Therapeutics (NASDAQ:SYRE) reported ($0.49) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.73) by $0.24. Learn more on analysts' earnings estimate vs. SYRE's actual earnings. How much revenue does Spyre Therapeutics generate each year? Spyre Therapeutics (NASDAQ:SYRE) has a recorded annual revenue of $890,000.00. How much profit does Spyre Therapeutics generate each year? Spyre Therapeutics (NASDAQ:SYRE) has a recorded net income of -$208.02 million. SYRE has generated -$3.40 earnings per share over the last four quarters. What is Spyre Therapeutics' EPS forecast for next year? Spyre Therapeutics' earnings are expected to grow from ($4.46) per share to ($3.99) per share in the next year. More Earnings Resources from MarketBeat Related Companies Akero Therapeutics Earnings Results ADMA Biologics Earnings Results Scholar Rock Earnings Results Mirum Pharmaceuticals Earnings Results ACADIA Pharmaceuticals Earnings Results Zai Lab Earnings Results Lantheus Earnings Results Indivior Earnings Results NewAmsterdam Pharma Earnings Results Centessa Pharmaceuticals Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings This page (NASDAQ:SYRE) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
